At least one early Pfizer study left a number of safety questions unanswered, questions that one might reasonably expect to be investigated as development of an mRNA vaccine progressed toward emergency authorization. Beginning in April 2020, Pfizer, together with study sponsor BioNTech, conducted a Phase 1/2 clinical trial designed to …